AstraZeneca 2020 forecasts hit by coronavirus, shares dive

Shares of the company, moving into a third year of growth after changes driven by Chief Executive Officer Pascal Soriot, sank 5% on Britain’s blue-chip index as it warned that the hit from the outbreak could last “a few months”. China was again a central driver for the company in the final quarter of 2019, with sales in the country growing 28% to $1.19 billion, making up 19% of total product sales in the period. The 2020 forecast was broadly in line with expectations, although some analysts have said anything less than double-digit sales growth would be a …read more

Source:: Yahoo Finance